Cancers have unique replication timing fingerprints that hold great promise as a novel genre of biomarkers, and despite the heterogeneity in different individual cancers, each cancer more closely resemble their tissue of origin than they do other tissue types. This phenomenon demonstrates the great promise of replication timing profiling to determine tissue of origin for metastatic cancers.
There are many biomarkers on the market for cancer and most involve tests for chromosome abnormalities while some involve gene expression tests. Currently biomarkers are only partially effective at diagnosis. Our technology provides a completely novel genre of biomarkers that cannot be detected by any other existing method.
This technology can provide a completely novel type of tissue of origin test, and queries the entire genome simultaneously and therefore is more comprehensive.